AC Immune
ACIU
51 hedge funds and large institutions have $139M invested in AC Immune in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 9 closing their positions.
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
35% more capital invested
Capital invested by funds: $102M → $139M (+$36.1M)
9% more funds holding
Funds holding: 47 → 51 (+4)
7% less call options, than puts
Call options by funds: $2.04M | Put options by funds: $2.19M
2.52% less ownership
Funds ownership: 27.56% → 25.04% (-2.5%)
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.84M |
| 2 |
Millennium Management
New York
|
+$1.65M |
| 3 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$1.49M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$855K |
| 5 |
CAM
Connacht Asset Management
New York
|
+$314K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$16.5M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.76M |
| 3 |
Renaissance Technologies
New York
|
-$1.09M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$988K |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$888K |
ACIU Hedge Fund Activity: Q1 2021 in Review
51 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q1 2021, worth a combined $139M — up 35% from $102M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ACIU positions and 9 closed out — a net gain of 4 holders — while 11 added to existing stakes and 18 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $8.84M. The largest seller was BVF Inc, cutting an estimated $16.5M.
- 51 institutional investors held AC Immune (ACIU) as of Q1 2021, up from 47 in Q4 2020.
- Funds reported $139M of AC Immune stock for Q1 2021, up 35% quarter-over-quarter.
- 13 funds opened new AC Immune positions in Q1 2021 and 9 closed out, a net change of +4 holders.
- The largest AC Immune buyer in Q1 2021 was EcoR1 Capital, an estimated $8.84M added.
- The largest AC Immune seller in Q1 2021 was BVF Inc, an estimated $16.5M sold.
Based on aggregated 13F filings for Q1 2021.